Phaseline

Targets › IFNAR1

IFNAR1 (Interferon alpha/beta receptor 1): drug programs, companies and trials

13 programs from 13 companies in 43 trials: 18 Phase 2, 16 Phase 3, 6 Phase 1, 3 Phase 4; Oncology, Infectious disease, Immunology; next expected readout Jan 2027.

Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. (UniProt, P17181)

Open in Phaseline: the race on IFNAR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaAnifrolumab
Interferon-alpha/beta receptor alpha chain antagonist
IFNAR1Phase 4Systemic Lupus Erythematosus; Systemic Sclerosis; Lupus Nephritis; Cutaneous Lupus Erythematosus …Jan 2027
PharmaEssentiaRopeginterferon Alfa-2B (P1101)
Interferon alpha/beta receptor positive modulator
IFNAR1, IFNAR2Phase 3Polycythemia Vera; Primary Myelofibrosis; Essential Thrombocythemia; Primary Myelofibrosis (PMF) …Mar 2027
BiogenPeginterferon Beta-1A (BIIB017)
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 3Multiple Sclerosis, Relapsing-RemittingMay 2027
BriaCell TherapeuticsInterferon Alfa-2B
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 3Breast Cancer; Colorectal Neuroendocrine Tumor G1; Prostate Adenocarcinoma; Polycythemia VeraDec 2027
University Hospital, MontpellierBeta-interferons
Type I interferon receptor agonist with immunomodulatory and anti-inflammatory effects
IFNAR1Phase 3Relapsing-Remitting Multiple Sclerosis (RRMS)Jun 2031
Xiamen Amoytop BiotechPeginterferon Alfa-2B
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2Essential Thrombocythemia; Hepatitis B, Chronic; Malignant MelanomaSep 2027
Brii BiosciencesPeginterferon Alfa-2A
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection; Chronic Hepatitis b; Chronic Hepatitis BSep 2028
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRetlirafusp alfa
Interferon alpha-2b variant that targets immune checkpoint pathways
IFNAR1Phase 2CRC (Colorectal Cancer)Jun 2029
Memorial Sloan Kettering Cancer CenterRopeginterferon
Pegylated interferon alpha
IFNAR1Phase 2Polycythemia Vera (PV)Oct 2029
Diakonos OncologyPeginterferon Alfa-2A
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2Glioblastoma (GBM)Mar 2030
M.D. Anderson Cancer CenterRecombinant Interferon Alpha 2b-like Protein
Type I interferon receptor agonist
IFNAR1, IFNAR2Phase 1Stage III Hepatocellular Carcinoma AJCC v8Feb 2028
Genrix (Shanghai) BiopharmaceuticalGR1603
Anti-IFNAR1 monoclonal antibody
IFNAR1Phase 1Lupus Erythematosus, SystemicJun 2028
Brigham and Women's HospitalRopeginterferon
Pegylated interferon alfa-2b with increased half-life
IFNAR1Phase 1JAK2 MutationAug 2030

Conditions

Systemic Lupus Erythematosus (6) Polycythemia Vera (3) Essential Thrombocythemia (3) Lupus Erythematosus, Systemic (2) Chronic Hepatitis b (2) Glioblastoma (GBM) (1) CRC (Colorectal Cancer) (1) Primary Myelofibrosis (1) Primary Myelofibrosis (PMF) (1) Chronic Myeloid Leukemia (1) Cutaneous T Cell Lymphoma (1) Ropeginterferon (1)

Modalities

mixed (6), protein or peptide (6), antibody (1)

Companies

Diakonos Oncology (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) PharmaEssentia (1) BriaCell Therapeutics (1) AstraZeneca (1) Genrix (Shanghai) Biopharmaceutical (1) Brigham and Women's Hospital (1) University Hospital, Montpellier (1) Brii Biosciences (1) Memorial Sloan Kettering Cancer Center (1) Xiamen Amoytop Biotech (1) Biogen (1) M.D. Anderson Cancer Center (1)

Related targets

IFNAR2 (7)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.